PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeffrey M. Leiden

Serial No.: 10/615,518

Filed: July 8, 2003

For: LONG TERM EXPRESSION OF GENE

PRODUCTS

Group Art Unit: 1632

Examiner: Falk, Anne Marie

Atty. Dkt. No.: BSX 302US3

Confirmation No.: 5333

CERTIFICATE OF ELECTRONIC TRANSMISSION

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

May 8, 2007

Date

Monica A. De La Paz

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/BSX 302US3.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,

Monica A. De La Paz Reg. No. 54,662

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

May 8, 2007

Form PTO-1449 (modified)				Atty. Docket No.: Serial No.: BSX 302US3 10/615,518					
List of Patents and Publications for Applicant's				Applicant:					
INFORMATION DISCLOSURE STATEMENT				Jeffrey M. Leiden					
INFORMATION DISCLOSURE STATEMENT				Filing Date: Group:					
	(Use s	everal sheets if necessary)	July 8, 2003 1632					
U.		Documents	_	atent Documents	Other Art				
See Page 1			See Page 1		See Page 1-2				
U.S. Patent Documents									
Exam.	Ref. Des.	Document Number	Date	Name	Cla		Sub Class	Filing Date	
	Des.	Number					Class	of App.	
Foreign Patent Documents									
Exam.	Ref.	Document	Date		.s 	7			
Init.	Des.	Number	Date	Country		Language		age	
(Other Art (Including Author, Title, Date Pertinent Pages, Etc.)								
Exam. Init.	Ref. Des.	Citation							
	C1	"Immunocompetent," Dictionary of Cancer Terms, National Cancer Institute, www.cancer.gov, downloaded May 4, 2007.							
	C2	Abo et al., "Differentiation stages of human natural killer cells in lymphoid tissues from fetal to adult life," J. Exp. Med., 157:273-284, 1983.							
	C3	Balasingam <i>et al.</i> , "Reactive Astrogliosis in the Neonatal Mouse Brain and Its Modulation by Cytokines," <i>J. Neuroscience</i> , 14:846-856, 1994.							
	C4	De Paoli et al., "Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population," Clin. Immunol. Immunopathol., 48:290-296, 1988.							
	C5	Hannet <i>et al.</i> , "Developmental and maturational changes in human blood lymphocyte subpopulations," <i>Immunol. Today</i> , 13:215-218, 1992.							
	C6	Kay et al., "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector," <i>Nature Genetics</i> , 24:257-261, 2000.							
	C7	Manno <i>et al.</i> , "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B," <i>Blood</i> , 101:2963-2972, 2003.							
	C8	Svensson <i>et al.</i> , "Muscle-based gene therapy: realistic possibilities for the future," <i>Mol. Med. Today</i> , 2:166-172, 1996.							
25774466.1									

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: BSX 302US3	Serial No.:	
List of Patents and Publications for	Applicant's	Applicant:		
Information Disclosure St	TATEMENT	Jeffrey M. Leiden		
(Use several sheets if necessar	ry)	Filing Date: July 8, 2003	Group: 1632	
		atent Documents	Other Art	
		e Page 1	See Page 1-2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation			
	C9	Wang and Herzog, "AAV-mediated gene transfer for treatment of hemophilia," <i>Current Gene Therapy</i> , 5:349-360, 2005.			
	C10	Yu and Unanue, "Macrophage Ontogeny: Implications for Host Defence, T-lymphocyte Differentiation, and the Acquisition of Self-tolerance," <i>Clin. Immunol. Allergy</i> , 5:253-269, 1985.			

25774466.1

EXAMINER: DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH